加载中
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
最新数据
US$28.4738
−US$0.5662 · -1.95%
盘中时间采用ET。市场数据可能有所延迟。
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
盘中时间采用ET。市场数据可能有所延迟。
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$39.00
上涨空间 36.97%报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB1025.77万0.10%108.2亿 USD0.44%US$201.3-1.45%
ALPS Medical Breakthroughs ETFSBIO190万1.02%1.87亿 USD0.50%US$52.465-2.57%
State Street SPDR Portfolio Developed World ex-US ETFSPDW188.83万0.00%406.96亿 USD0.03%US$49.665-0.04%
Virtus Biotech ETFBBP169.02万1.31%1.31亿 USD0.34%US$101.56-2.00%
Tema Oncology ETFCANC134.4万0.66%2.03亿 USD0.99%US$39.605-2.40%
State Street SPDR S&P International Small Cap ETFGWX120.98万0.13%9.15亿 USD0.40%US$45.1347-0.28%
Fidelity Nasdaq Composite Index ETFONEQ58.55万0.01%109.4亿 USD0.21%US$107.23-0.12%
iShares International Small-Cap Equity Factor ETFISCF51.53万0.08%6.6亿 USD0.24%US$44.40+0.11%iShares Biotechnology ETFIBBALPS Medical Breakthroughs ETFSBIOState Street SPDR Portfolio Developed World ex-US ETFSPDWVirtus Biotech ETFBBPTema Oncology ETFCANCState Street SPDR S&P International Small Cap ETFGWXFidelity Nasdaq Composite Index ETFONEQiShares International Small-Cap Equity Factor ETFISCFAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
